Peptides for energy and mitochondria covers a research area where the readouts are unusually concrete: oxygen consumption rate, membrane potential, ATP output, NAD+/NADH ratio and respiratory complex activity are all directly measurable, which makes this one of the few peptide goals where mechanistic claims can be closed properly. The compounds divide into mitochondrial-derived signalling peptides, membrane-targeting tetrapeptides, redox cofactors, and a set of small molecules that act on the same pathways without being peptides at all. This overview separates them by mechanism, compares the reference standards researchers specify, and explains what each format can and cannot answer. All material is supplied for laboratory research use only.
What "mitochondrial function" means as a measured endpoint
Bioenergetics research has a standard toolkit, and the compounds discussed here are usually judged against it. Extracellular flux analysis gives basal and maximal oxygen consumption rate, spare respiratory capacity, proton leak and ATP-linked respiration in intact cells. Membrane potential is read with TMRM or JC-1. Mitochondrial content is estimated from mtDNA copy number or citrate synthase activity, and biogenesis from PGC-1α expression. Reactive oxygen species production is measured with MitoSOX or Amplex Red. Cellular NAD+ and NADH are quantified by enzymatic NAD assay or LC-MS/MS.
The distinction that matters most is between capacity and efficiency. An uncoupler raises oxygen consumption while lowering ATP yield per oxygen consumed — that is the point of it. A cardiolipin-stabilising compound aims for the opposite: the same or lower oxygen consumption with better coupling. Reporting oxygen consumption alone, without the coupling ratio, cannot distinguish those two outcomes and is the single most common reporting failure in this area.
The classes studied
Mitochondrial-derived peptides
MOTS-c is a 16-residue peptide, 2174.55 Da, encoded within the mitochondrial 12S rRNA gene — a genuinely unusual origin. Published work reports AMPK activation, inhibition of the folate-methionine pathway with consequent effects on purine biosynthesis, and translocation to the nucleus under metabolic stress where it influences stress-response gene expression. Humanin, 2687.27 Da, was identified in 2001 from the mitochondrial 16S rRNA region and is studied principally for cytoprotection against apoptotic stimuli, acting at a receptor complex involving gp130 and CNTFR. Both are studied as retrograde signals — mitochondria communicating status to the nucleus and to distant tissues — rather than as bioenergetic agents in the direct sense.
Membrane-targeting tetrapeptides
SS-31, elamipretide, is the most mechanistically resolved compound in this whole area. It is a 639.80 Da alternating aromatic-cationic tetrapeptide that concentrates in the inner mitochondrial membrane through an interaction with cardiolipin, the signature phospholipid of that membrane. By stabilising cardiolipin-protein interactions it is reported to improve cristae architecture and electron transport chain supercomplex assembly, which is a mechanism that predicts improved coupling rather than raised capacity — and that is what the flux data shows. It is also the compound here with the most advanced human trial programme.
NAD, redox cofactors and NNMT inhibition
NAD+ is the electron carrier that the entire oxidative pathway depends on, and its age-related decline is among the best-documented observations in metabolic biology. Precursors such as NMN and NR raise circulating NAD+ metabolites reliably in human studies; the functional consequences remain unsettled. 5-Amino-1MQ, 159.21 Da, works on the same currency from a different direction: it inhibits nicotinamide N-methyltransferase, the enzyme that methylates nicotinamide and diverts it away from NAD+ salvage. Rodent work reports increased cellular NAD+ and reduced adipocyte size. Methylene blue acts as an alternative electron carrier that can bypass complex I-III at low concentrations, with a well-documented hormetic concentration-response that reverses at higher concentrations.
AMPK activators, ERR agonists and uncouplers
AICAR, 258.23 Da, is the classic AMP-mimetic AMPK activator and remains the reference compound for that pathway in cell work despite well-known off-target effects. SLU-PP-332, 290.27 Da, is a pan-agonist of the estrogen-related receptors, published from Saint Louis University as increasing oxidative metabolism in mice through a transcriptional rather than an allosteric mechanism. BAM15, 322.29 Da, is a mitochondrial protonophore uncoupler selected for a wider therapeutic window than dinitrophenol; in flux experiments it is used deliberately to dissipate membrane potential.
What the published record shows, by study type
Cell and isolated mitochondria
This is where the strongest data sits. SS-31 improves respiratory efficiency in permeabilised fibres and isolated mitochondria across several independent groups. MOTS-c activates AMPK in myotubes and hepatocytes with a measurable shift in substrate utilisation within hours. AICAR and BAM15 behave as their mechanisms predict and are routinely used as positive controls for AMPK activation and uncoupling respectively. Humanin's cytoprotection is reproducible in serum-deprivation and amyloid-toxicity models.
Rodent studies
MOTS-c has published effects on exercise capacity and metabolic parameters in aged mice. SLU-PP-332 has reported increases in running capacity and oxidative gene expression. 5-Amino-1MQ has rodent adiposity and NAD data. SS-31 has cardiac and renal ischaemia-reperfusion data from multiple laboratories. The general weakness across these studies is inconsistent reporting of mitochondrial content, without which a change in tissue respiration cannot be attributed to per-mitochondrion function rather than to more mitochondria.
Human data
Elamipretide has completed registered trials in primary mitochondrial myopathy and has been studied in Barth syndrome and geographic atrophy. It holds no marketing approval. NAD precursor trials are numerous and consistently show metabolite elevation. Methylene blue has long-standing approved use in methaemoglobinaemia at defined clinical concentrations, which is a different context from its bioenergetic research use. MOTS-c, humanin, SLU-PP-332, BAM15 and AICAR have no controlled human efficacy evidence.
Comparison table: mitochondrial and energy research standards
| Compound | Class | MW | Reported mechanism | Typical readout | Research sizes |
|---|---|---|---|---|---|
| MOTS-c | Mitochondrial-derived peptide | 2174.55 Da | AMPK activation, folate pathway | OCR, AMPK phosphorylation | 5-40 mg |
| Humanin | Mitochondrial-derived peptide | 2687.27 Da | gp130/CNTFR cytoprotection | Apoptosis and viability assays | 5 mg, 10 mg |
| SS-31 (elamipretide) | Cardiolipin-binding tetrapeptide | 639.80 Da | Cristae and supercomplex stabilisation | Coupling efficiency, ATP/O | 10-50 mg |
| NAD+ | Redox cofactor | 663.43 Da | Electron carrier, sirtuin substrate | NAD+/NADH ratio | 100-1000 mg |
| 5-Amino-1MQ | NNMT inhibitor | 159.21 Da | Blocks nicotinamide methylation | Cellular NAD+, adipocyte size | 50 mg, 100 mg |
| AICAR | AMP mimetic | 258.23 Da | Allosteric AMPK activation | ACC phosphorylation | 50 mg, 100 mg |
| SLU-PP-332 | ERR pan-agonist | 290.27 Da | Transcriptional oxidative programme | PGC-1α, running capacity | 5 mg, 10 mg |
| BAM15 | Protonophore uncoupler | 322.29 Da | Dissipates proton gradient | Maximal OCR, membrane potential | 15 mg capsules |
| Methylene blue | Alternative electron carrier | 319.85 Da | Redox shuttling, complex bypass | OCR, hormetic concentration-response | 5-25 mg capsules |
Only the first three entries are peptides. The rest are small molecules included because they act on the same pathways and are the comparators reviewers expect to see in bioenergetics work.
How researchers choose peptides for energy and mitochondria
- Capacity or efficiency? Uncouplers raise capacity and lower efficiency; cardiolipin-targeting compounds do the reverse. The question determines the compound, and both need the coupling ratio reported, not oxygen consumption alone.
- Is the target a signalling pathway or the organelle itself? MOTS-c and humanin are signalling molecules with nuclear and receptor-level effects; SS-31 and BAM15 act on the membrane directly. Only the latter group produces effects in isolated mitochondria stripped of nuclear machinery.
- Is a positive control required? AICAR for AMPK, BAM15 or FCCP for uncoupling, and oligomycin for ATP synthase inhibition are the expected reference points; a bioenergetics manuscript without them is difficult to interpret.
- Does mitochondrial content need normalising? If biogenesis is part of the hypothesis, respiration must be normalised to citrate synthase activity or mtDNA copy number, or the result is uninterpretable.
Everything catalogued for this research goal is listed under peptides for energy and mitochondria, with the narrower peptide grouping under mitochondrial peptides. The two compounds most often compared directly are covered in our MOTS-c versus SS-31 comparison.
Formats and handling
Lyophilised vials are standard for the peptides and allow molar concentrations to be set precisely — necessary here because the molecular weights range from 159 Da to nearly 2,700 Da and equimolar comparisons are the norm in flux work. Oral capsule formats exist for methylene blue, BAM15, 5-Amino-1MQ and the NAD precursors, reflecting that these are small molecules with real oral bioavailability rather than peptides. Nasal and dissolving-strip formats for NAD+ are pre-diluted preparations at fixed concentration; they remove reconstitution steps and remove concentration control at the same time.
Handling is stricter in this class than most. NAD+ oxidises in solution and is light-sensitive, so working solutions are prepared fresh rather than stored. Methylene blue stains everything it touches and interferes optically with colorimetric and fluorescent assays at the wavelengths many kits use — a genuine practical problem, not a nuisance. AICAR and BAM15 need DMSO or similar for stock preparation, and the vehicle concentration must be matched in controls because DMSO itself affects respiration above roughly 0.1%. Lyophilised peptides are stored sealed at -20 °C, protected from light, and aliquoted at reconstitution.
Adjacent compounds researchers ask about
Several materials appear in the same protocols without belonging to the classes above. L-carnitine and its acyl esters are substrate-transport cofactors rather than signalling molecules: they move long-chain fatty acids across the inner membrane, so they change what the mitochondrion oxidises rather than how well it oxidises. CoQ10 is an endogenous electron carrier between complexes I/II and III, and its supplementation logic depends entirely on whether the model is actually deficient — in a replete system it will do very little, which explains a good deal of the inconsistency in the literature. B-vitamin cofactors, particularly riboflavin and niacin derivatives, are precursors to FAD and NAD respectively and are relevant where the hypothesis concerns cofactor availability rather than enzyme function.
Grouping these with the mitochondrial peptides is a matter of shared application. Mechanistically they sit upstream, at substrate supply and cofactor availability, and an experiment that confounds a supply limitation with a functional deficit will produce a result that does not replicate in a differently fed model.
Common design errors
Reporting oxygen consumption without the coupling ratio heads the list, for the reason set out above. Second is failing to normalise to mitochondrial content, which makes it impossible to separate more mitochondria from better mitochondria. Third is ignoring vehicle effects: DMSO, ethanol and even elevated buffer osmolarity change respiration measurably, and vehicle-matched controls are not optional in flux assays.
Fourth, and specific to methylene blue, is failing to test a concentration range. Its concentration-response is biphasic — electron-carrying at low concentrations, oxidising and inhibitory at higher ones — so a single-concentration experiment can produce the opposite of the expected result and be reported as a negative finding.
Purity, identity and regulatory status
The peptides here should show 98% or better by HPLC with mass-spectrometric identity confirmation; MOTS-c and humanin at 16 and 24 residues are within routine synthetic range. For the small molecules, purity by HPLC or GC with an identity method is the relevant specification, and a CAS number that matches the catalogue entry is the first thing to check — several of these compounds have close structural analogs that are cheaper to source.
None of the compounds described is approved as an energy or mitochondrial intervention. Elamipretide has reached registered human trials without approval. Methylene blue holds an approval for methaemoglobinaemia at defined clinical concentrations, which does not extend to research use in bioenergetics. AICAR and the ERR agonists are prohibited in competitive sport. All material referenced is research-grade, for in-vitro and laboratory use only, and is not for human or veterinary administration.